about
Drug induced exfoliative dermatitis: state of the artAortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura.The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases.Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity.Kaposi's Sarcoma in a Patient with Eosinophilic Granulomatosis with Polyangiitis While Taking Mycophenolate Mofetil.Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.EBV-induced lymphoproliferative disorders in rheumatic patients: A systematic review of the literature.Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study.Painful fingers.BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis.A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report.Diagnosing Erdheim-Chester disease.Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.Assessment of tocilizumab in the treatment of cancer cachexia.Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study.Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.Tocilizumab in patients with multisystem Erdheim-Chester disease.Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor.Orthopnea with platydeoxia secondary to prominent Eustachian valve.Hospitalisation rates among patients with primary Sjögren's syndrome: a population-based study, 1995-2016.Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.Erdheim-Chester disease.Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort StudyMethotrexate in refractory bilateral juvenile temporal arteritis: Report of a caseAssociation of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort StudySevere/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitisIncidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohortBrief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Distinct genetic subsets in ANCA-associated vasculitisJuxta-vertebral lesions in granulomatosis with polyangiitisUpdate on the epidemiology, risk factors, and outcomes of systemic vasculitidesClinical Characterization and Predictors of IOS-Defined Small-Airway Dysfunction in AsthmaEosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the diseaseRemission maintenance in ANCA-associated vasculitis: does one size fit all?The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated VasculitisOrbital masses in ANCA-associated vasculitis: an unsolved challenge?The severe long-term outcomes of 'non-severe' eosinophilic granulomatosis with polyangiitis
P50
Q26739886-7E71BB11-631B-4521-BD42-8CA46AB2F236Q33415801-E0588859-25E2-40D6-9DC1-D9CCB49FD3C0Q38080428-218847F2-13B4-4233-8E69-74D767D395D1Q38295425-33BBEE82-73A7-4E4F-A338-C3014C889BC7Q38327494-2A020988-9FA6-4AA9-A337-B52AD7B0AD4DQ38405591-FD7A319C-FA67-4956-921C-5B7150FD1775Q38961694-B2B460F8-000C-4C25-B753-210E9E10FA81Q39397373-4FD41665-6667-4581-A7D3-9773BB101833Q40053425-FAB967A5-1D18-4D6C-A543-B084CE986B60Q40130189-5681B710-030E-4AA8-9771-55D36D560A29Q40180256-83351806-1441-492D-821B-F77A43633E34Q42209164-B22B1443-5B60-4465-A34A-8304564F866CQ42293496-1535D875-9717-40AA-8670-C8186818ECD1Q45961800-806DE4F7-D7FA-41CE-A5DF-5C4172AC7B20Q47699328-F448E4E7-8311-4CFD-A4C3-6A062F6C3F0AQ49826180-AFDF46FA-0999-4523-B69D-574A734CACF8Q50865592-A2343072-3408-4D15-B651-53A6AA588696Q52560921-71F0760B-B150-44CB-B30F-6719EE95F532Q52678711-1FE33347-18A3-4970-BA7B-CEAC59A70D50Q52763513-52361F11-5FEB-45C5-AFD6-BCD6F5AC346FQ52808597-65123A71-4B01-48B0-A0EC-D271DBE8361BQ53650885-5246CC20-2B54-45BC-9D52-B35C75136C6EQ53837951-EF51C00E-1BB7-4735-9092-E3CE4A8614CAQ54597476-5BBB7532-2AF5-467F-BD3D-C55694231AF7Q55061555-B49FE7B8-331E-4743-9279-B7B9EE469DD7Q56243435-285350B2-B6B4-4A54-BE00-98CA890CE42CQ60609592-147AA30F-F9A1-40CB-818F-0BE3E4E05B83Q64041359-9E0461CE-0B57-4A7E-8B6F-0CDDC6735E32Q64043428-6574B829-34B3-40C7-A46B-5E551E903C04Q64043729-8AE5E0EA-6B0D-42D7-8D5C-8313BFA76ABDQ64996266-7A619D7D-FDC4-4226-ACEB-D4E17FCC0BABQ87421488-BCF827E8-52D9-47BF-98C1-C48F343BAFCBQ88249764-1B7BF0F2-0683-46B7-8723-73E7478537B6Q90346739-498E0F54-E679-4622-99A7-0D105B2CB8ADQ91281368-6DBF6B6D-F66E-4B88-BA8D-EF42F60FA87AQ91425297-9D245E9B-D197-46EA-B33A-89EBAFCA771BQ91425306-4741C471-A3FD-4385-99E1-2E9739AF6017Q91528632-72F92186-B8E0-44EC-9C0B-C930961D6964Q92025318-8EA821E4-14D8-4866-A000-4B1E55720722Q93140181-0DAC5694-CE0C-49EC-A29D-2C7F879B195E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alvise Berti
@ast
Alvise Berti
@en
Alvise Berti
@es
Alvise Berti
@nl
type
label
Alvise Berti
@ast
Alvise Berti
@en
Alvise Berti
@es
Alvise Berti
@nl
prefLabel
Alvise Berti
@ast
Alvise Berti
@en
Alvise Berti
@es
Alvise Berti
@nl
P106
P31
P496
0000-0002-7831-921X